Allegiant Gold (AUXXF)(AUAU:CA) – Bureau of Land Management Approval Increases Permitted Area Six-Fold

Wednesday, September 29, 2021

Allegiant Gold (AUXXF)(AUAU:CA)
Bureau of Land Management Approval Increases Permitted Area Six-Fold

Allegiant Gold is a mid-stage exploration stage company with 10 highly prospective projects in the southwest United States, including 7 projects in the State of Nevada. Allegiant’s flagship project is Eastside, a district-scale project in Nevada with inferred resources of 1.4 million gold and 8.8 million silver ounces of inferred resources and significant potential to add size and scale. The company’s shares trade on the TSX Venture Exchange under the ticker symbol “AUAU” and on the OTCQX under the ticker symbol “AUXXF.”

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Bureau of Land Management approval. Allegiant Gold received Bureau of Land Management approval to significantly expand its drilling activities and operations at its flagship Eastside project in Nevada. Allegiant is now able to expand drilling beyond the existing original pit zone as well as around a recently discovered high-grade zone.

    Significantly expands the permitted area.  The first permit expands the plan-of-operations to 3,676 acres from 600 acres around the original pit zone. The second permit amends the existing drill target plan within the original pit zone and will allow Allegiant to drill up to 14 new diamond core holes to test the recently discovered high-grade zone announced in May. Allegiant is now able to construct …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Release – Orion Group Holdings Inc Announces Contract Awards of Approximately $22 Million Value Could Increase

 


Orion Group Holdings, Inc. Announces Contract Awards of Approximately $22 Million; Value Could Increase

 

HOUSTON–(BUSINESS WIRE)–Sep. 28, 2021– 
Orion Group Holdings, Inc. (NYSE: ORN) (the “Company”) a leading specialty construction company, today announced three contract awards totaling approximately 
$22 million.

The Company’s Marine segment has been awarded three contracts valued at a combined 
$22 million to perform dredging services for the 
US Army Corps of Engineers (USACE) in waterways along the gulf coast, with the potential for the contract value on one award to increase by up to 
$19 million.

Two of these contracts were recently awarded by the USACE’s 
Galveston District for dredging work on the 
Texas coast. The first award valued at 
$8.8 million calls for the removal of up to two million cubic yards of maintenance material along the 
Gulf Intracoastal Waterway between 
Corpus Christi and 
Port Isabel. The second award, located in the 
Sabine Neches Waterway in 
Jefferson County, Texas, is valued at a base amount of 
$9.5 million for the dredging of 2.1 million cubic yards of material. If the USACE exercises all options for additional scope of work, the total value for this contract could grow to over 
$28 million.

The third award is a 
$3.5 million contract from the USACE’s 
Jacksonville District to dredge maintenance material from the upper channels in 
Tampa Harbor, in 
Tampa, Florida. Work on all three projects is expected to commence during the fourth quarter of 2021, with completion expected late next year.

“Maintaining our nation’s waterways is critical to the economy of our country and being able to continue to support the 
US Army Corps of Engineers in executing their mission is equally critical to Orion,” said  Mark Stauffer, Orion’s President and Chief Executive Officer. “We have several ongoing projects for the 
US Army Corps of Engineers and the addition of these projects adds to the growing backlog in our marine business.”

About Orion Group Holdings

Orion Group Holdings, Inc., a leading specialty construction company serving the infrastructure, industrial and building sectors, provides services both on and off the water in the continental 
United States
Alaska
Canada and the 
Caribbean Basin through its marine segment and its concrete segment. The Company’s marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. Its concrete segment provides turnkey concrete construction services including pour and finish, dirt work, layout, forming, rebar, and mesh across the light commercial, structural and other associated business areas. The Company is headquartered in 
Houston, Texas with regional offices throughout its operating areas.

Forward-Looking Statements

The matters discussed in this press release may constitute or include projections or other forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the provisions of which the Company is availing itself. Certain forward-looking statements can be identified by the use of forward-looking terminology, such as ‘believes’, ‘expects’, ‘may’, ‘will’, ‘could’, ‘should’, ‘seeks’, ‘approximately’, ‘intends’, ‘plans’, ‘estimates’, or ‘anticipates’, or the negative thereof or other comparable terminology, or by discussions of strategy, plans, objectives, intentions, estimates, forecasts, outlook, assumptions, or goals. In particular, statements regarding future operations or results, including those set forth in this press release and any other statement, express or implied, concerning future operating results or the future generation of or ability to generate revenues, income, net income, profit, EBITDA, EBITDA margin, or cash flow, including to service debt, and including any estimates, forecasts or assumptions regarding future revenues or revenue growth, are forward-looking statements. Forward looking statements also include estimated project start date, anticipated revenues, and contract options which may or may not be awarded in the future. Forward looking statements involve risks, including those associated with the Company’s fixed price contracts that impacts profits, unforeseen productivity delays that may alter the final profitability of the contract, cancellation of the contract by the customer for unforeseen reasons, delays or decreases in funding by the customer, levels and predictability of government funding or other governmental budgetary constraints and any potential contract options which may or may not be awarded in the future, and are the sole discretion of award by the customer. Past performance is not necessarily an indicator of future results. In light of these and other uncertainties, the inclusion of forward-looking statements in this press release should not be regarded as a representation by the Company that the Company’s plans, estimates, forecasts, goals, intentions, or objectives will be achieved or realized. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update information contained in this press release whether as a result of new developments or otherwise.

Please refer to the Company’s Annual Report on Form 10-K, filed on 
March 2, 2021, which is available on its website at www.oriongroupholdingsinc.com or at the SEC’s website at www.sec.gov, for additional and more detailed discussion of risk factors that could cause actual results to differ materially from our current expectations, estimates or forecasts.

Orion Group Holdings Inc.
Francis Okoniewski, Vice President Investor Relations
(346) 616-4138
fokoniewski@orn.net
www.oriongroupholdingsinc.com

Robert Tabb, Executive Vice President & CFO
(713) 852-6500
www.oriongroupholdingsinc.com

Source: 
Orion Group Holdings, Inc.

Release – FenixOro Drills 23.2 gt Gold in Newly Discovered Cascada Vein


FenixOro Drills 23.2 g/t Gold in Newly Discovered Cascada Vein, Significantly Increases Resource Potential on Northwest Corridor at Abriaqui Gold Deposit

 

TORONTO, Sept. 28, 2021 (GLOBE NEWSWIRE) — FenixOro Gold Corp (CSE:FENX, OTCQB:FDVXF, Frankfurt:8FD) is pleased to announce that following lengthy delays caused by Covid 19-related issues in the Lima Peru lab, final assays have been received for the first three holes, along with partial results for the fourth, from the initial Phase 2 infill drill holes on the Northwest Vein Corridor (NWC) of the Abriaqui gold deposit. These results significantly increase the Company’s previously stated potential resource expectations and assumptions (see press release dated March 19, 2021).

Highlights include:

  • New high grade “Cascada” vein intersected 1.3m @ 23.23 g/t gold and is part of a newly defined WNW trend of at least four veins (see Figure 1)
  • Three main veins in the northwest corridor have an increase in average grade x thickness values 55%, 25%, and 20% higher than in previous resource potential estimates
  • Three new veins intersected deeper mineralization including 1.3m @ 19.47 g/t gold
  • Hole 14, currently in progress, is targeting mineralization up to 250 meters below the deepest drill intercept to date
  • The current resource model incorporates only 4 of the 120 known, mapped veins on the project. New data from Phase 2 drilling will allow the Company to incorporate 10 or more vein structures
  • Preparation underway for maiden drilling in the highly prospective southeastern license (see press release dated May 10, 2021)
  • Eight and ten veins respectively intersected in holes P010 and P012 (a re-drill of P011 which was lost)

FenixOro VP Exploration Stuart Moller commented, “We are extremely pleased with these first results of the NWC infill drill program as the higher average grades and thicknesses significantly increase resource potential on previously modeled veins. Our understanding of the Santa Teresa “vein” is also becoming much more clear: it is really a series of parallel veins within a corridor up to 15 meters wide, flanked and separated by a variably developed zone of veinlets and stockwork mineralization.”

Mr. Moller continued: “It was a significant surprise that we intersected four new veins within 150 meters of previous drill holes. The high grade Cascada vein and three new veins in the bottom of P012 add significantly to resource potential and more work is being done to include these in our formal model. Following this Phase 2 program we should be in a position to begin formal resource-definition spaced drilling on the NWC with the goal of defining a maiden resource on as many as ten veins, an increase from the four that are currently being modelled. Preparation is also underway to begin the first drill holes in the highly prospective southeastern block.”

New WNW Trending Vein Structure Identified
The newly designated “Cascada” vein was cut in P013. The intersection was 1.3m @ 23.23 g/t gold. It is different from most other veins at Abriaqui in that it has a low content of sulfides, low silver, and contains visible gold. Cascada appears to be part of a family of at least four veins which trend 290 degrees. These veins have not been mapped on surface and are known only from underground workings and the new intersection in P013. They appear intermittently between the major veins of the NWC which trend 315 degrees (Figure 1). Their geometry is not well enough understood to justify individual longitudinal sections at this point, but they appear to have higher than project-average gold grade and they offer significant upside potential to be evaluated in future drilling.

Three additional new veins were discovered in the bottom of hole P012. This “footwall series” of veins averages 1.5m in thickness with gold grades up to 19.47 g/t. (Table 2). These too are not yet well-understood geometrically and represent additional potential which will require deeper drilling to define.

Four plus holes have been drilled in Phase 2 for 2575 meters with a project total of 6604 meters in 14 holes (Table 1, Figure 1). P010 – P013 were drilled from the same pad as P001 as part of an infill program to begin the resource definition program on the northwest trending vein corridor (NWC). Holes were drilled at -45 degrees except for P012 and P014 which are angled at -65 degrees for deeper tests of the system. P011 was lost at 136 meters and P012 is a re-drill of that hole.

Table 2 highlights the principal gold-bearing intercepts in NWC drilling to date including newly reported values for P010 – P012 and the upper part of P013. P010 was drilled to the west to cover the gap between P001 and P005 and eight significant veins were intersected. P012 was drilled at a steeper angle to test the same vein package at depth. Ten veins were intersected with the deepest still carrying high grade at the 1540 meter elevation which matches the deepest drilled mineralization in the district to date. Hole P014 (in progress) is projected to intersect the deepest veins in the NWC at the 1300 meter elevation.

Table 1: 

Figure 1: 

Table 2: 

Resource Development Progress
Though no formal resource calculation has been done in the project area, FenixOro presented a series of longitudinal sections supporting an early estimate of resource potential on four veins in the Press Release of March 19, 2021. The three of those sections which are part of the NWC are updated here with the new drill data and results of recent underground channel sampling. The Santa Teresa Vein system is the largest in the NWC. It is really a series of parallel veins within a corridor up to 15 meters wide flanked and separated by a variably developed zone of veinlets and stockwork mineralization. As seen in Figure 2, we now have five data points defining the potential resource block including four drill holes and a channeled interval from a mine working (see Press Release of August 6, 2021). The average grade times thickness parameter (GxT, Table 3) for these points is 53% greater than in the March 19 estimate and our degree of confidence in that number is significantly higher given the larger data set.

Figure 3 shows the Orquidea Vein in longitudinal section (NWC4 vein in the earlier presentation). The four drill intersections average 1.86m @ 12.68 g/t gold with a GxT 24% higher than that used in the initial assessment. Figure 4 presents the Romperopa 1 Vein (NWC5). The three intersections average 2.45m @ 8.32 g/t gold with a GxT 20% higher than the previous value.

The yellow minimum resource potential blocks in each section are defined by the position of the drill holes and channeled interval, samples in shallow mine workings, the Cascada Fault on the southeast, and the 1500m elevation at depth. Areas of additional potential are shown with red arrows. These will be evaluated with ongoing step-out drilling laterally and at depth as indicated by the projected pierce points of the remaining Phase 2 drill holes shown in blue. The mineralization is open at depth below 1540m and the expectation is that there is significant room for resource growth downward on all veins. Hole P014 (in progress) is projected to intersect the deeper veins at about the 1300m elevation. Hole P009 from Phase 1 and visual inspection of the lower part of P013 (assays pending) indicate that the veins of the NWC continue to the southeast of the Cascada Fault and there is excellent potential for multiple mineralized veins in that direction.

Phase 2 drilling will continue with at least two more infill holes on the NWC, one infill hole on the EWC, and 4-5 holes in the highly prospective southeast license. The program is scheduled to continue into Q1 2022.

Figure 2: 

Figure 3: 

Figure 4: 

Table 3: 

Technical Information
Stuart Moller, Vice President Exploration and Director of the Company and a Qualified Person for the purposes of NI 43-101 (P.Geo, British Colombia), has prepared or supervised the preparation of the technical information contained in this press release. Mr. Moller has more than 40 years of experience in exploration for precious and other metals including ten in Colombia and is a Fellow of the Society of Economic Geologists.

Drill core sampling is done in accordance with industry standards. The HQ and NQ diameter core is sawed, and half core samples are submitted to the laboratory. The other half core along with laboratory coarse reject material and sample pulps are stored in secure facilities on site and/or in the sample prep lab. Following strict chain of custody protocols, the samples are driven to the ISO 17025:2017 certified ALS Laboratory sample preparation facility in Medellin and ALS ships the prepared pulps to their assay laboratory in Lima, Peru. Blanks, duplicates, and certified reference standards totaling 15% of the total samples are inserted into the sample stream. To date, no material quality control issues have been detected. Gold is analyzed by fire assay with 50 gram charges for grades in excess of 10 grams per tonne and the additional elements are analyzed by ICP with appropriate follow-up for over- limits.

Reported grade intervals are calculated using uncut gold values. Maximum sample length is one meter. Intervals which include multiple samples are calculated using the full geologic interval of mineralization and are not subject to specific rules for cutoff grades and internal low grade. As such, quoted thickness and grade of these intervals do not necessarily represent optimized economic intervals in a potential future mine. Reported sample and interval widths are based on lengths of individual samples in core and do not necessarily represent true widths of mineralization. True widths will sometimes be less than the quoted interval lengths.

There are currently no NI 43-101 compliant resources or reserves in the project area. The analysis of drill results is intended to estimate the potential for future resources which will require significant additional drilling to define.

The comparison between Abriaqui and the nearby Buritica project is meant only to indicate the similarities between the two in terms of geological setting. FenixOro does not imply that exploration results and/or economic characteristics of a potential future mine at Abriaqui will be similar to those seen at Buritica.

About FenixOro Gold Corp.
FenixOro Gold Corp is a Canadian company focused on acquiring and exploring gold projects with world class exploration potential in the most prolific gold producing regions of Colombia. FenixOro’s flagship property, the Abriaqui project, is located 15 km west of Continental Gold’s Buritica project in Antioquia State at the northern end of the Mid-Cauca gold belt, a geological trend which has seen multiple large gold discoveries in the past 10 years including Buritica and Anglo Gold’s Nuevo Chaquiro and La Colosa. As documented in “NI 43-101 Technical Report on the Abriaqui project Antioquia State, Colombia” (December 5, 2019), the geological characteristics of Abriaqui and Buritica are similar. The report also documents the high gold grade at Abriaqui with samples taken from 20 of the veins assaying greater than 20 g/t gold. Since the preparation of this report a Phase 1 drilling program has been completed at Abriaqui resulting in a significant discovery of a high grade, “Buritica style” gold deposit. A Phase 2 drilling program has recently commenced.

FenixOro’s VP of Exploration, Stuart Moller, led the discovery team at Buritica for Continental Gold in 2007-2011. At the time of its latest public report, the Buritica Mine contains measured plus indicated resources of 5.32 million ounces of gold (16.02 Mt grading 10.32 g/t) plus a 6.02 million ounce inferred resource (21.87 Mt grading 8.56 g/t) for a total of 11.34 million ounces of gold resources. Buritica began formal production in November 2020 and has expected annual average production of 250,000 ounces at an all-in sustaining cost of approximately US$600 per ounce. Resources, cost and production data are taken from Continental Gold’s “NI 43-101 Buritica Mineral Resource 2019-01, Antioquia, Colombia, 18 March, 2019″). Continental Gold was recently the subject of a takeover by Zijin Mining in an all-cash transaction valued at C$1.4 billion.

Forward Looking Information
This news release contains certain forward-looking information. All statements included herein, other than statements of historical fact, are forward-looking information and such information involves various risks and uncertainties. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. Specifically, this news release contains forward looking information regarding the significance of Phase 1 drill results at the Abriaqui Project, conclusions as to resource potential derived from that data set, potential results of the Phase 2 drill program, and implied assumptions as to the potential future economic viability of the gold grades and vein thicknesses reported. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. Although FenixOro has no reason to believe otherwise, there can be no assurance that the Phase 2 drill program and potential future resource definition drilling will be completed as uncertainties exist related to future project financing and future environmental permitting. Although FenixOro has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be additional factors that cause results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking information.

FenixOro Gold Corp
John Carlesso, CEO
Email: info@FenixOro.com
Website: www.FenixOro.com
Telephone: 1-833-ORO-GOLD

Item 9 Labs (INLB) – Expanding Unity Rd. Footprint

Tuesday, September 28, 2021

Item 9 Labs (INLB)
Expanding Unity Rd. Footprint

Item 9 Labs Corp. (OTCQX: INLB) is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The award-winning Item 9 Labs brand specializes in best-in-class products and user experience across several cannabis categories. The company also offers a unique dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. Item 9 Labs brings the best industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation. The veteran management team combines a diverse skill set with deep experience in the cannabis sector, franchising, and the capital markets to lead a new generation of public cannabis companies that provide transparency, consistency, and well-being. Headquartered in Arizona, the company is currently expanding its operations space by 650,000+ square feet on its 50-acre site, one of the largest properties in Arizona zoned to grow and cultivate flower. For additional information, visit item9labscorp.com.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    New Agreements. Item 9 Labs announced continued development of its cannabis dispensary franchise brand, Unity Rd., across the Northeastern United States with new signed agreements for development in New Jersey and Virginia and the signing of a lease for the first Unity Rd. dispensary in Maine by an existing partner. Unity Rd. has multiple agreements signed with more than 15 entrepreneurial groups who are in various stages of development across eight states.

    New Jersey.  Adult use was approved by voters in November 2020 and in August regulators approved initial rules for the program that will set up the state’s retail market. The New Jersey market is projected to hit around $750 million of sales in the first full year growing to $2.1 billion in the fourth year …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Grindrod Shipping (GRIN) – Secondary Offering Improves Public Market Float

Tuesday, September 28, 2021

Grindrod Shipping (GRIN)
Secondary Offering Improves Public Market Float

Grindrod Shipping, originated in South Africa with roots dating back to 1910. The company is based in Singapore, with offices around the world including, London, Durban, Cape Town, Tokyo and Rotterdam. Its primary listing is on Nasdaq and secondary listing on the JSE.

Grindrod Shipping owns and operates a diversified fleet of owned, long-term chartered and joint-venture dry-bulk and liquid-bulk vessels across the globe.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Secondary offering enhances trading liquidity.  Grindrod Limited, the former parent, sold 1.84 million shares last week in a secondary offering at $13.50/share pursuant to a F-3 filing dated August 23rd. While the offering was priced at a 14% discount to the previous closing price, the stock rebounded quickly and closed yesterday ~13% above the offering price. We view the offering favorably since the public market float increased to 13.1 million shares, or 68%, and trading liquidity is likely to improve.

    No change to current 2021-2 EBITDA estimates and variable dividend policy on horizon.  Our 4Q2021 dividend estimate is $0.61/share, including cash of $0.54/share and buybacks of $0.07/share. As highlighted in recent notes, the variable dividend will consist of a combo of buybacks and cash. As of August 30th, 91,871 shares were bought back at an average $14.87/share so total dividend will include …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S. Berger, M.D. as Chief Medical Officer and Hemant Kumar, Ph.D. as Chief Manufacturing and Technology Officer


Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S. Berger, M.D. as Chief Medical Officer and Hemant Kumar, Ph.D. as Chief Manufacturing and Technology Officer

 

Seasoned innovative drug development executives bolster leadership with relevant domain expertise as Company advances key Acclaim-1 and Acclaim-2 clincial trials of REQORSA systemic gene therapy in non-small cell lung cancer and works to expand technology pipeline

AUSTIN, Texas — (September 28, 2021) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Company has strengthened its leadership team with the appointments of Mark S. Berger, M.D. to the newly-created position of Chief Medical Officer and Hemant Kumar, Ph.D., CPM, EMBA to the newly-created position of Chief Manufacturing and Technology Officer.  Drs. Berger and Kumar will report to  Rodney Varner, Chief Executive Officer of Genprex. 

“It is my priviledge and pleasure to welcome Mark and Hemant to our management team.  Their collective accomplishments and deep domain expertise in clinical development and gene therapy manufacturing, respectively, will be of great value as they help guide Genprex and advance our important Acclaim-1 and Acclaim-2 clinical trials in non-small cell lung cancer this year,” stated Mr. Varner.  “As we continue to make progress with these studies, and to expand our technology pipeline, it is more important than ever to have medical affairs and manufacturing in such capable hands.”

“I am delighted to join the growing team at Genprex, confident that my experience designing and managing pivotal clinical trials in oncology will provide valuable insight and oversight for Genprex’ novel gene therapy pipeline,” commented Dr. Berger. “Advancing the first systemic gene therapy in oncology is  a uniquely exciting opportunity to transform cancer care for patients with limited treatment options and I am looking forward to working with Genprex’ leadership team to help develop this new approach to cancer treatment.”  

“I am delighted to join the management team at Genprex and to work alongside this group of seasoned executives to realize the potential for its novel systemic gene therapy to improve outcomes for cancer patients,” noted Dr. Kumar.  “I am eager to apply my expertise and technical background in accelerated development of innovative biologics and advanced cell and gene therapies to support Genprex’ already impressive work and drive its technologies to commercialization.” 

About Mark S. Berger

Dr. Berger is an oncologist and senior executive with 25 years of biotech and pharmaceutical company experience in the development of oncology therapeutics.  He has successfully brought two drugs through the regulatory process to approval and excels in strategic development, team management and collaborative leadership. Dr. Berger joins Genprex from Actinium Pharmaceuticals, Inc. where since January 2017 he served as Chief Medical Officer and was responsible for clinical strategy and development of radioisotope-labeled antibodies for therapy in oncology, including the Company’s Phase 3 SIERRA trial.  Before that, Dr. Berger was Senior Vice President-Clinical Research at Kadmon Corporation from 2013 through 2017, where he led all aspects of the company’s new drug development, including clinical trial design and management of the oncology programs in non-small cell lung cancer and breast cancer, among others. 

Prior to that, Dr. Berger was Chief Medical Officer of Deciphera Pharmaceuticals from June 2011 to September 2013. Before Deciphera, Dr. Berger was Vice President for Clinical Development at Gemin X Pharmaceuticals, where he led the clinical strategy, design and management of clinical trials for two novel oncology agents including obatoclax. Based on the results of a randomized Phase 2 clinical trial of obatoclax, Gemin X was acquired by Cephalon in March of 2011. Before his work with biotechnology companies, Dr. Berger held key positions in two global pharmaceutical companies. Dr. Berger previously served as Group Director, Medicine Development Centre-Oncology for GlaxoSmithKline. In this position Dr. Berger managed the development of Tykerb (lapatinib) in lung and breast cancer where he designed and led two Phase 2 clinical trials before planning and leading a 399 patient pivotal Phase 3 trial that resulted in the FDA approval of Tykerb in breast cancer. In addition, he managed the Lapatinib Expanded Access Program that enrolled over 4000 patients on a global basis. Dr. Berger began his career in drug development at Wyeth Research where he led the planning and execution of the pivotal Phase 2 trial for Mylotarg, which was the first antibody targeted chemotherapy agent. He presented the Mylotarg clinical data at the FDA’s Oncology Drug Advisory Committee meeting, after which Mylotarg received accelerated FDA approval for patients with relapsed AML.

Dr. Berger holds a B.A. in biology from Wesleyan University and a M.D. from the University of Virginia School of Medicine. He did his Hematology/Oncology fellowship at the University of Pennsylvania, where he was an Assistant Professor of Medicine, and also was a Research Fellow at the Ludwig Institute for Cancer Research and the Imperial Cancer Research Fund, both in London. Dr. Berger is board certified in internal medicine, hematology and medical oncology. 

About Hemant Kumar, Ph.D., CPM, EMBA

Dr. Kumar is a recognized global expert in Chemistry, Manufacture and Controls (CMC) Technical Development and GMP manufacturing.  He has a greater than 25-year track record leading global CMC and regulatory approval strategy for accelerated development of innovative vaccines, biologics, advanced cell & gene therapy drug process and product development (Ph1 to Ph3 and commercialization) under current GMP, and licensing processes. Dr. Kumar joins Genprex from Arcturus Therapeutics, Inc., where he served as Strategic Advisor and then Vice President, Global Head of Manufacturing, Supply Chain, and Strategy.  Prior to that, Dr. Kumar was Vice President of CMC Technical Development & Manufacturing Operations at Oncoimmune Therapeutics, Inc., a private company that was acquired by Merck & Co. during his tenure there.  Before that, he was Vice President, Head of Global Process Sciences and Clinical Manufacturing Operations at Rentscher BioPharma, SE.  Previous to that, Dr. Kumar was with Anaptysbio, Inc., where he served as Senior Vice President, Head of Global CMC, Technical Development and Manufacturing Operations.   Before that, Dr. Kumar held senior level positions of increasing manufacturing and technical operations leadership in global biopharmaceutical companies including Merck & Co., Inc.,  Sanofi Genzyme, Inc., Lonza Biologics, Inc., Sanofi Pasteur, Janssen Biotech ( a Johnson & Johnson company) and Wyeth Lederle Vaccines, Inc.

Dr. Kumar earned his Ph.D. in Biochemistry at J.N. Medical College, Aligarth India through a collaboration with the U.S. National Institutes of Health. He holds a graduate certificate in Project Management from Lehigh University School of Management.  Dr. Kumar has conducted postdoctoral and research scientist fellowships at Yale University School of Medicine, the University of Rhode Island and the Center for Disease Control and Prevention’s Center for Infectious Diseases.  He holds professional affilations with the American Chemical Society, American Association for the Advancement of Science, Americal Society for Microbiology and the International Society of Pharmaceutical Engineers.  

Inducement Grants

The Company has granted 550,000 options to Dr. Berger at an exercise price equal to $2.85, the closing price of our common stock on September 27, 2021, the date of grant. While these options were not granted under Genprex’s 2018 Equity Incentive Plan (the “Plan”), the awards will incorporate the terms of the Plan.  The options vest as to one-third of the shares over the next three years and are exercisable for a period of ten years subject to continued service to the Company.

The Company has granted 400,000 options to Dr. Kumar at an exercise price equal to $2.85, the closing price of our common stock on September 27, 2021, the date of grant. While these options were not granted under the Plan, the awards will incorporate the terms of the Plan.  The options vest as to one-third of the shares over the next three years and are exercisable for a period of ten years subject to continued service to the Company.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its unique, proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform used for cancer in humans. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is then administered intravenously, where it is then taken up by tumor cells that express proteins that are deficient. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with AstraZeneca’s Tagrisso® (osimertinib) for patients with EFGR mutations whose tumors progressed after treatment with Tagrisso.

For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on TwitterFacebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex’s reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under “Item 1A – Risk Factors” in Genprex’s Annual Report on Form 10-K.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the timing and success of Genprex’s clinical trials and regulatory approvals; the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes;  Genprex’s future growth and financial status; Genprex’s commercial and strategic partnerships including the scale up of the manufacture of its product candidates; and Genprex’s intellectual property and licenses.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.

(877) 774-GNPX (4679)

Investor Relations

GNPX Investor Relations

(877) 774-GNPX (4679) ext. #2

investors@genprex.com

Media Contact

Genprex Media Relations

Anne Marie Fields

(877) 774-GNPX (4679) ext. #3

afields@rxir.com

Release – Allegiant Receives Final BLM Approval At Flagship Eastside Project, Increasing Permitted Area By 600 Percent


Allegiant Receives Final BLM Approval At Flagship Eastside Project, Increasing Permitted Area By 600%

 

also receives amended drilling permit for follow-up drilling at RECENT high-grade discovery AT EASTSIDE

Reno, Nevada /September 28, 2021 – Allegiant Gold Ltd. (“Allegiant” or the “Company”) (AUAU: TSX-V) (AUXXF: OTCQX) is very pleased to announce the receipt of two permits allowing for a significant expansion of drilling and operations at its Flagship Eastside Project (Inferred ounces of 1.4M Au and 8.7M Ag*) near the town of Tonopah, Nevada. The first permit expands the Plan-of-Operations (“PoO”) from the previous 600 acres to over 3,676 acres around the Original Pit Zone. The second permit received amends the existing drill target plan within the Original Pit Zone and will allow Allegiant to drill up to 14 new diamond core holes to test the recently discovered high-grade zone announced on May 26, 2021. Highlights of that announcement included:

  • Strong gold intercepts in Holes 239, 243, 244 and 245
  • Mineralization encountered in 7 of 9 holes
  • Significant silver in Holes 243 and 239
  • Hole 243 included 2.55 g/t Au over 147.8 metres (3.17 g/t Au over 117.3m)
  • Hole 239 included 111.3m of 1.45 g/t Au including 3.1 metres of 39 g/t at the bottom of the hole.
  • Hole 244 included 76 metres of mineralization with best intercept being 6.1m of 1.48 g/t Au
  • Hole 245 included 15.2 metres of 3.4 g/t Au from relatively shallow depths (177m)
  • Eastside remains open in all directions and at depth in both the Original Pit Zone and the Castle Zone

Peter Gianulis, CEO of Allegiant Gold, commented: “The receipt of the two permits is a major development that will allow us to further expand beyond the existing Original Pit Zone at Eastside as well as offset drilling around the recently discovered high-grade zone. We embarked on this expanded Plan-of-Operations over 18 months ago with the plan of testing geochemical and geophysical anomalies that have never been previously drilled. We look forward to executing our business plan which includes significant drilling.”

The newly approved PoO allows Allegiant to build new roads and access to 160 new drill sites to test gold, arsenic, and intense hydrothermal alteration zones continuing south and west of the existing resource for at least 2-3 km. It also allows Allegiant to drill geophysical anomalies on the pediment east of our existing resource which are interpreted to be rhyolite domes known to be key for hosting gold at Eastside. Allegiant plans to provide a comprehensive update on the business plan and the upcoming drilling in the near future.

*The updated resource estimate (“Updated Resource Estimate and NI 43-101 Technical Report, Eastside and Castle Gold-Silver Project Technical Report, Esmeralda County, Nevada”) was conducted by Mine Development Associates (“MDA”), a division of RESPEC of Reno, Nevada with an effective date of July 30, 2021. Contained pit-constrained Inferred Resources (cut-off grade of 0.15 g/t) of 1,090,000 Au ounces in 61,730,000 tonnes at 0.55 g/t Au and 8,700,000 Ag ounces at 4.4 g/t Ag at the Original Pit Zone and 314,000 Au ounces in 19,986,000 tonnes at 0.49 g/t Au at the Castle Area. In accordance with NI 43-101, the MDA Technical Report dated July 30, 2021, will be filed on SEDAR. This report builds on and supersedes the NI 43-101 reports of Ristorcelli (December 2016), Ristorcelli (July 2017) and Ristorcelli (January 2020) titled “Amended Updated Resource Estimate and NI 43-101 Technical Report, Eastside and Castle Gold-Silver Project, Esmeralda County, Nevada” prepared for Allegiant with an Effective Date of December 30, 2019.

See Eastside expanded permit area here:

Map 1: Expanded Permit Area Map
https://allegiantgold.com/site/assets/files/2209/eastside-expanded-permit-area-map.jpg

QUALIFIED PERSON

Andy Wallace is a Certified Professional Geologist (CPG) with the American Institute of Professional Geologists and is the Qualified Person under NI 43-101, Standards of Disclosure for Mineral Projects, who has reviewed and approved the scientific and technical content of this press release.

ABOUT ALLEGIANT

Allegiant owns 100% of 10 highly-prospective gold projects in the United States, 7 of which are located in the mining-friendly jurisdiction of Nevada. Four of Allegiant’s projects are farmed-out, providing for cost reductions and cash-flow. Allegiant’s flagship, district-scale Eastside project hosts a large and expanding gold resource and is located in an area of excellent infrastructure. Preliminary metallurgical testing indicates that both oxide and sulphide gold mineralization at Eastside is amenable to heap leaching.

ON BEHALF OF THE BOARD

Peter Gianulis
CEO

For more information contact:
Investor Relations
(604) 634-0970 or
1-888-818-1364
ir@allegiantgold.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain statements and information contained in this press release constitute “forward-looking statements” within the meaning of applicable U.S. securities laws and “forward-looking information” within the meaning of applicable Canadian securities laws, which are referred to collectively as “forward-looking statements”. The United States Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for certain forward-looking statements.Allegiant Gold Ltd.’s (“Allegiant”) exploration plans for its gold exploration properties, the drill program at Allegiant’s Eastside project, the preparation and publication of an updated resource estimate in respect of the Original Zone at the Eastside project, Allegiant’s future exploration and development plans, including anticipated costs and timing thereof; Allegiant’s plans for growth through exploration activities, acquisitions or otherwise; and expectations regarding future maintenance and capital expenditures, and working capital requirements. Forward-looking statements are statements and information regarding possible events, conditions or results of operations that are based upon assumptions about future economic conditions and courses of action. All statements and information other than statements of historical fact may be forward-looking statements. In some cases, forward-looking statements can be identified by the use of words such as “seek”, “expect”, “anticipate”, “budget”, “plan”, “estimate”, “continue”, “forecast”, “intend”, “believe”, “predict”, “potential”, “target”, “may”, “could”, “would”, “might”, “will” and similar words or phrases (including negative variations) suggesting future outcomes or statements regarding an outlook. Such forward-looking statements are based on a number of material factors and assumptions and involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or industry results, to differ materially from those anticipated in such forward-looking information. You are cautioned not to place undue reliance on forward-looking statements contained in this press release. Some of the known risks and other factors which could cause actual results to differ materially from those expressed in the forward-looking statements are described in the sections entitled “Risk Factors” in Allegiant’s Listing Application, dated January 24, 2018, as filed with the TSX Venture Exchange and available on SEDAR under Allegiant’s profile at www.sedar.com. Actual results and future events could differ materially from those anticipated in such statements. Allegiant undertakes no obligation to update or revise any forward-looking statements included in this press release if these beliefs, estimates and opinions or other circumstances should change, except as otherwise required by applicable law.

Source: Allegiant Gold Ltd.

Allegiant Receives Final BLM Approval At Flagship Eastside Project, Increasing Permitted Area By 600%


Allegiant Receives Final BLM Approval At Flagship Eastside Project, Increasing Permitted Area By 600%

 

also receives amended drilling permit for follow-up drilling at RECENT high-grade discovery AT EASTSIDE

Reno, Nevada /September 28, 2021 – Allegiant Gold Ltd. (“Allegiant” or the “Company”) (AUAU: TSX-V) (AUXXF: OTCQX) is very pleased to announce the receipt of two permits allowing for a significant expansion of drilling and operations at its Flagship Eastside Project (Inferred ounces of 1.4M Au and 8.7M Ag*) near the town of Tonopah, Nevada. The first permit expands the Plan-of-Operations (“PoO”) from the previous 600 acres to over 3,676 acres around the Original Pit Zone. The second permit received amends the existing drill target plan within the Original Pit Zone and will allow Allegiant to drill up to 14 new diamond core holes to test the recently discovered high-grade zone announced on May 26, 2021. Highlights of that announcement included:

  • Strong gold intercepts in Holes 239, 243, 244 and 245
  • Mineralization encountered in 7 of 9 holes
  • Significant silver in Holes 243 and 239
  • Hole 243 included 2.55 g/t Au over 147.8 metres (3.17 g/t Au over 117.3m)
  • Hole 239 included 111.3m of 1.45 g/t Au including 3.1 metres of 39 g/t at the bottom of the hole.
  • Hole 244 included 76 metres of mineralization with best intercept being 6.1m of 1.48 g/t Au
  • Hole 245 included 15.2 metres of 3.4 g/t Au from relatively shallow depths (177m)
  • Eastside remains open in all directions and at depth in both the Original Pit Zone and the Castle Zone

Peter Gianulis, CEO of Allegiant Gold, commented: “The receipt of the two permits is a major development that will allow us to further expand beyond the existing Original Pit Zone at Eastside as well as offset drilling around the recently discovered high-grade zone. We embarked on this expanded Plan-of-Operations over 18 months ago with the plan of testing geochemical and geophysical anomalies that have never been previously drilled. We look forward to executing our business plan which includes significant drilling.”

The newly approved PoO allows Allegiant to build new roads and access to 160 new drill sites to test gold, arsenic, and intense hydrothermal alteration zones continuing south and west of the existing resource for at least 2-3 km. It also allows Allegiant to drill geophysical anomalies on the pediment east of our existing resource which are interpreted to be rhyolite domes known to be key for hosting gold at Eastside. Allegiant plans to provide a comprehensive update on the business plan and the upcoming drilling in the near future.

*The updated resource estimate (“Updated Resource Estimate and NI 43-101 Technical Report, Eastside and Castle Gold-Silver Project Technical Report, Esmeralda County, Nevada”) was conducted by Mine Development Associates (“MDA”), a division of RESPEC of Reno, Nevada with an effective date of July 30, 2021. Contained pit-constrained Inferred Resources (cut-off grade of 0.15 g/t) of 1,090,000 Au ounces in 61,730,000 tonnes at 0.55 g/t Au and 8,700,000 Ag ounces at 4.4 g/t Ag at the Original Pit Zone and 314,000 Au ounces in 19,986,000 tonnes at 0.49 g/t Au at the Castle Area. In accordance with NI 43-101, the MDA Technical Report dated July 30, 2021, will be filed on SEDAR. This report builds on and supersedes the NI 43-101 reports of Ristorcelli (December 2016), Ristorcelli (July 2017) and Ristorcelli (January 2020) titled “Amended Updated Resource Estimate and NI 43-101 Technical Report, Eastside and Castle Gold-Silver Project, Esmeralda County, Nevada” prepared for Allegiant with an Effective Date of December 30, 2019.

See Eastside expanded permit area here:

Map 1: Expanded Permit Area Map
https://allegiantgold.com/site/assets/files/2209/eastside-expanded-permit-area-map.jpg

QUALIFIED PERSON

Andy Wallace is a Certified Professional Geologist (CPG) with the American Institute of Professional Geologists and is the Qualified Person under NI 43-101, Standards of Disclosure for Mineral Projects, who has reviewed and approved the scientific and technical content of this press release.

ABOUT ALLEGIANT

Allegiant owns 100% of 10 highly-prospective gold projects in the United States, 7 of which are located in the mining-friendly jurisdiction of Nevada. Four of Allegiant’s projects are farmed-out, providing for cost reductions and cash-flow. Allegiant’s flagship, district-scale Eastside project hosts a large and expanding gold resource and is located in an area of excellent infrastructure. Preliminary metallurgical testing indicates that both oxide and sulphide gold mineralization at Eastside is amenable to heap leaching.

ON BEHALF OF THE BOARD

Peter Gianulis
CEO

For more information contact:
Investor Relations
(604) 634-0970 or
1-888-818-1364
ir@allegiantgold.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain statements and information contained in this press release constitute “forward-looking statements” within the meaning of applicable U.S. securities laws and “forward-looking information” within the meaning of applicable Canadian securities laws, which are referred to collectively as “forward-looking statements”. The United States Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for certain forward-looking statements.Allegiant Gold Ltd.’s (“Allegiant”) exploration plans for its gold exploration properties, the drill program at Allegiant’s Eastside project, the preparation and publication of an updated resource estimate in respect of the Original Zone at the Eastside project, Allegiant’s future exploration and development plans, including anticipated costs and timing thereof; Allegiant’s plans for growth through exploration activities, acquisitions or otherwise; and expectations regarding future maintenance and capital expenditures, and working capital requirements. Forward-looking statements are statements and information regarding possible events, conditions or results of operations that are based upon assumptions about future economic conditions and courses of action. All statements and information other than statements of historical fact may be forward-looking statements. In some cases, forward-looking statements can be identified by the use of words such as “seek”, “expect”, “anticipate”, “budget”, “plan”, “estimate”, “continue”, “forecast”, “intend”, “believe”, “predict”, “potential”, “target”, “may”, “could”, “would”, “might”, “will” and similar words or phrases (including negative variations) suggesting future outcomes or statements regarding an outlook. Such forward-looking statements are based on a number of material factors and assumptions and involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or industry results, to differ materially from those anticipated in such forward-looking information. You are cautioned not to place undue reliance on forward-looking statements contained in this press release. Some of the known risks and other factors which could cause actual results to differ materially from those expressed in the forward-looking statements are described in the sections entitled “Risk Factors” in Allegiant’s Listing Application, dated January 24, 2018, as filed with the TSX Venture Exchange and available on SEDAR under Allegiant’s profile at www.sedar.com. Actual results and future events could differ materially from those anticipated in such statements. Allegiant undertakes no obligation to update or revise any forward-looking statements included in this press release if these beliefs, estimates and opinions or other circumstances should change, except as otherwise required by applicable law.

Source: Allegiant Gold Ltd.

Stem Holdings (STMH)(STEM:CA) – California E-Commerce and Delivery Expansion

Tuesday, September 28, 2021

Stem Holdings (STMH)(STEM:CA)
California E-Commerce and Delivery Expansion

Stem Holdings Inc is engaged in the purchasing, improving, and leasing of properties and finance assets which are operated by third parties and are used for the cultivation and retail sale of marijuana. Its properties includes 42nd Street, and Mulino Farm which are used for agriculture. The company generates its revenue in the form of rental income from tenants.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    California Expansion. On the heels of last weeks expansion in Oregon, Driven by Stem has received a non-storefront license to open a distribution hub in Mendota, located in the county of Fresno, enabling it to provide better service to consumers with its Budee e-commerce platform in four key counties in Northern California, home to 2.3 million residents.

    Benefits.  The expansion is expected to drive topline sales with greater efficiency, as the Company anticipates savings of up to $1 million in operating expenses, with significant savings in gross receipt taxes. The Company plans for the Mendota hub to become operational in October through a new 2,000 square foot facility, which will be dedicated to delivery service in 60 minutes or less …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Aurania Resources (AUIAF)(ARU:CA) – Hole 3 Delivers at Tiria-Shimpia

Tuesday, September 28, 2021

Aurania Resources (AUIAF)(ARU:CA)
Hole 3 Delivers at Tiria-Shimpia

As of April 24, 2020, Noble Capital Markets research on Aurania Resources is published under ticker symbols (AUIAF and ARU:CA). The price target is in USD and based on ticker symbol AUIAF. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.

Aurania Resources Ltd. is a Canada-based junior mining exploration company engaged in the identification, evaluation, acquisition, and exploration of mineral property interests, with a focus on precious metals and copper. Its flagship asset, The Lost Cities-Cutucu Project, is in southeastern Ecuador in the Province of Morona-Santiago. The company also has several minor projects in Switzerland.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Encouraging Tiria-Shimpia drill results. The third hole drilled on the Tiria-Shimpia silver-zinc target intersected the top of a targeted layer of brecciated limestone at a depth of 35 meters. Mineralization was revealed over 29 meters at a grade of 3.5 grams of silver per tonne and 0.6% zinc, including a 5-meter interval at a grade of 10.5 grams of silver per tonne and 2.5% zinc. The goal is to identify the higher-grade parts of the system within the 22-kilometer-long trend defined by metal enrichment in soil. Soil geochemistry and Mobile MT data are being used to refine the target for higher-grade mineralization. Hole 3 was drilled approximately 2 kilometers to the north of where holes SH-001 and SH-002 were drilled. A total of 1,018 meters has been drilled in the three holes completed at Tiria-Shimpia.

    Eighth hole being drilled at Tsenken N1.  Hole TSN1-007 at the Tsenken N1 sediment-hosted copper-silver target has been completed and drilling at Hole TSN1-008 has been started. We think management intends to complete 10 drill holes at Tsenken N1 …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Release – Genprex Strengthens Management Team with Appointments of Industry Leaders


Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S. Berger, M.D. as Chief Medical Officer and Hemant Kumar, Ph.D. as Chief Manufacturing and Technology Officer

 

Seasoned innovative drug development executives bolster leadership with relevant domain expertise as Company advances key Acclaim-1 and Acclaim-2 clincial trials of REQORSA systemic gene therapy in non-small cell lung cancer and works to expand technology pipeline

AUSTIN, Texas — (September 28, 2021) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Company has strengthened its leadership team with the appointments of Mark S. Berger, M.D. to the newly-created position of Chief Medical Officer and Hemant Kumar, Ph.D., CPM, EMBA to the newly-created position of Chief Manufacturing and Technology Officer.  Drs. Berger and Kumar will report to  Rodney Varner, Chief Executive Officer of Genprex. 

“It is my priviledge and pleasure to welcome Mark and Hemant to our management team.  Their collective accomplishments and deep domain expertise in clinical development and gene therapy manufacturing, respectively, will be of great value as they help guide Genprex and advance our important Acclaim-1 and Acclaim-2 clinical trials in non-small cell lung cancer this year,” stated Mr. Varner.  “As we continue to make progress with these studies, and to expand our technology pipeline, it is more important than ever to have medical affairs and manufacturing in such capable hands.”

“I am delighted to join the growing team at Genprex, confident that my experience designing and managing pivotal clinical trials in oncology will provide valuable insight and oversight for Genprex’ novel gene therapy pipeline,” commented Dr. Berger. “Advancing the first systemic gene therapy in oncology is  a uniquely exciting opportunity to transform cancer care for patients with limited treatment options and I am looking forward to working with Genprex’ leadership team to help develop this new approach to cancer treatment.”  

“I am delighted to join the management team at Genprex and to work alongside this group of seasoned executives to realize the potential for its novel systemic gene therapy to improve outcomes for cancer patients,” noted Dr. Kumar.  “I am eager to apply my expertise and technical background in accelerated development of innovative biologics and advanced cell and gene therapies to support Genprex’ already impressive work and drive its technologies to commercialization.” 

About Mark S. Berger

Dr. Berger is an oncologist and senior executive with 25 years of biotech and pharmaceutical company experience in the development of oncology therapeutics.  He has successfully brought two drugs through the regulatory process to approval and excels in strategic development, team management and collaborative leadership. Dr. Berger joins Genprex from Actinium Pharmaceuticals, Inc. where since January 2017 he served as Chief Medical Officer and was responsible for clinical strategy and development of radioisotope-labeled antibodies for therapy in oncology, including the Company’s Phase 3 SIERRA trial.  Before that, Dr. Berger was Senior Vice President-Clinical Research at Kadmon Corporation from 2013 through 2017, where he led all aspects of the company’s new drug development, including clinical trial design and management of the oncology programs in non-small cell lung cancer and breast cancer, among others. 

Prior to that, Dr. Berger was Chief Medical Officer of Deciphera Pharmaceuticals from June 2011 to September 2013. Before Deciphera, Dr. Berger was Vice President for Clinical Development at Gemin X Pharmaceuticals, where he led the clinical strategy, design and management of clinical trials for two novel oncology agents including obatoclax. Based on the results of a randomized Phase 2 clinical trial of obatoclax, Gemin X was acquired by Cephalon in March of 2011. Before his work with biotechnology companies, Dr. Berger held key positions in two global pharmaceutical companies. Dr. Berger previously served as Group Director, Medicine Development Centre-Oncology for GlaxoSmithKline. In this position Dr. Berger managed the development of Tykerb (lapatinib) in lung and breast cancer where he designed and led two Phase 2 clinical trials before planning and leading a 399 patient pivotal Phase 3 trial that resulted in the FDA approval of Tykerb in breast cancer. In addition, he managed the Lapatinib Expanded Access Program that enrolled over 4000 patients on a global basis. Dr. Berger began his career in drug development at Wyeth Research where he led the planning and execution of the pivotal Phase 2 trial for Mylotarg, which was the first antibody targeted chemotherapy agent. He presented the Mylotarg clinical data at the FDA’s Oncology Drug Advisory Committee meeting, after which Mylotarg received accelerated FDA approval for patients with relapsed AML.

Dr. Berger holds a B.A. in biology from Wesleyan University and a M.D. from the University of Virginia School of Medicine. He did his Hematology/Oncology fellowship at the University of Pennsylvania, where he was an Assistant Professor of Medicine, and also was a Research Fellow at the Ludwig Institute for Cancer Research and the Imperial Cancer Research Fund, both in London. Dr. Berger is board certified in internal medicine, hematology and medical oncology. 

About Hemant Kumar, Ph.D., CPM, EMBA

Dr. Kumar is a recognized global expert in Chemistry, Manufacture and Controls (CMC) Technical Development and GMP manufacturing.  He has a greater than 25-year track record leading global CMC and regulatory approval strategy for accelerated development of innovative vaccines, biologics, advanced cell & gene therapy drug process and product development (Ph1 to Ph3 and commercialization) under current GMP, and licensing processes. Dr. Kumar joins Genprex from Arcturus Therapeutics, Inc., where he served as Strategic Advisor and then Vice President, Global Head of Manufacturing, Supply Chain, and Strategy.  Prior to that, Dr. Kumar was Vice President of CMC Technical Development & Manufacturing Operations at Oncoimmune Therapeutics, Inc., a private company that was acquired by Merck & Co. during his tenure there.  Before that, he was Vice President, Head of Global Process Sciences and Clinical Manufacturing Operations at Rentscher BioPharma, SE.  Previous to that, Dr. Kumar was with Anaptysbio, Inc., where he served as Senior Vice President, Head of Global CMC, Technical Development and Manufacturing Operations.   Before that, Dr. Kumar held senior level positions of increasing manufacturing and technical operations leadership in global biopharmaceutical companies including Merck & Co., Inc.,  Sanofi Genzyme, Inc., Lonza Biologics, Inc., Sanofi Pasteur, Janssen Biotech ( a Johnson & Johnson company) and Wyeth Lederle Vaccines, Inc.

Dr. Kumar earned his Ph.D. in Biochemistry at J.N. Medical College, Aligarth India through a collaboration with the U.S. National Institutes of Health. He holds a graduate certificate in Project Management from Lehigh University School of Management.  Dr. Kumar has conducted postdoctoral and research scientist fellowships at Yale University School of Medicine, the University of Rhode Island and the Center for Disease Control and Prevention’s Center for Infectious Diseases.  He holds professional affilations with the American Chemical Society, American Association for the Advancement of Science, Americal Society for Microbiology and the International Society of Pharmaceutical Engineers.  

Inducement Grants

The Company has granted 550,000 options to Dr. Berger at an exercise price equal to $2.85, the closing price of our common stock on September 27, 2021, the date of grant. While these options were not granted under Genprex’s 2018 Equity Incentive Plan (the “Plan”), the awards will incorporate the terms of the Plan.  The options vest as to one-third of the shares over the next three years and are exercisable for a period of ten years subject to continued service to the Company.

The Company has granted 400,000 options to Dr. Kumar at an exercise price equal to $2.85, the closing price of our common stock on September 27, 2021, the date of grant. While these options were not granted under the Plan, the awards will incorporate the terms of the Plan.  The options vest as to one-third of the shares over the next three years and are exercisable for a period of ten years subject to continued service to the Company.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its unique, proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform used for cancer in humans. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is then administered intravenously, where it is then taken up by tumor cells that express proteins that are deficient. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with AstraZeneca’s Tagrisso® (osimertinib) for patients with EFGR mutations whose tumors progressed after treatment with Tagrisso.

For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on TwitterFacebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex’s reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under “Item 1A – Risk Factors” in Genprex’s Annual Report on Form 10-K.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the timing and success of Genprex’s clinical trials and regulatory approvals; the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes;  Genprex’s future growth and financial status; Genprex’s commercial and strategic partnerships including the scale up of the manufacture of its product candidates; and Genprex’s intellectual property and licenses.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.

(877) 774-GNPX (4679)

Investor Relations

GNPX Investor Relations

(877) 774-GNPX (4679) ext. #2

investors@genprex.com

Media Contact

Genprex Media Relations

Anne Marie Fields

(877) 774-GNPX (4679) ext. #3

afields@rxir.com

What Evergrande Confirmed About Gold and Bitcoin


Gold Maintained Its Haven Status During the Evergrande Selloff

 

It’s the biggest company you’ve never heard of—until last week, that is. Evergrande Group, the “too big to fail” Chinese property developer, rattled markets last Monday when it missed interest payments to at least two of its lenders. This gave more than a few investors flashbacks to Lehman Brothers’ demise in 2008, which helped trigger the global financial crisis.

 

This article was republished with permission
from Frank Talk, a CEO Blog by Frank Holmes of U.S. Global Investors (
GROW). Find more of Frank’s articles here – Originally published September 27, 2021

 

The selloff spread to U.S. markets, and I was pleased to see that gold maintained its haven status. The yellow metal ended the day slightly up more than half a percent, passing an important “stress test” of its investment case in the age of Bitcoin.

The world’s biggest cryptocurrency, believed by many to be “digital gold,” plunged 8.5% on Monday as investors dumped riskier assets. Indeed, Bitcoin is more than four times as volatile as gold. Those of you who attended HIVE Blockchain Technologies’ earnings webcast on Friday know that gold bullion has a 10-day standard deviation of only ±3, while Bitcoin’s is ±14. Ether’s is even higher at ±19 over 10 trading days.

Bitcoin dipped further last week after the Chinese government banned all crypto transactions and crypto mining, prompting many to speculate that the People’s Bank of China (PBOC) is preparing to issue its own CBDC, or central
bank digital currency.

I believe this crackdown is yet more proof that people need to own some Bitcoin, which is currently on sale as we await news on whether the Xi Jinping Administration will step in to prevent another pandemic, this one of the financial kind.

Gold and Bitcoin Looking More Attractive as Contagion Fears Mount

For the record, I find it hard to believe that President Xi will do nothing. Evergrande may not be a household name in the U.S., but it’s China’s second largest real estate company, with nearly 800 projects in 234 cities. It also offers financial products, invests in electric vehicles and is even building a theme park on an artificial
island off the province of Hainan.

This growth didn’t happen organically, though, and today Evergrande is believed to be the world’s most indebted developer, saddled with more than $300 billion in total liabilities. In November 2020, the Financial
Times
 wrote that the Fortune 500 company “has enough land to house the entire population of Portugal and more debt than New Zealand.” At the end of last year, it had roughly twice as much debt as equity, putting it in a class well above other Chinese real estate firms. 

As “eye-popping” as Evergrande’s debt load is, it’s a “small drop in the ocean of debt that the world is swimming in,” CLSA’s Damian Kestel wrote last week in a note to clients. Total global debt in the second quarter stood at just under $300 trillion, a new record, according to the Institute of International Finance’s (IFF) most recent Global Debt Monitor.

“The bigger they come, the harder they fall,” as the saying goes. If Evergrande were allowed to fail without any governmental intervention, it could spark a credit crisis that would make 2007-2008 look tame by comparison.

Against this backdrop, gold and Bitcoin look very attractive to me as stores of value, and both happen to be on sale right now. I’ve always recommended a 10% weighting in gold, with 5% in bullion and 5% in gold mining stocks and ETFs. I also believe it’s prudent to have between 1% and 2% in Bitcoin.

No, They’re Not Mutually Exclusive

As someone who’s involved in both gold and Bitcoin investing, I clearly don’t subscribe to the idea that one is better than the other in all cases. I agree with Bloomberg’s James Seyffart and Eric Balchunas, who said in a note last week that gold and Bitcoin “can complement each other in a portfolio.”

Although the two assets share
obvious similarities and differences
 – one is thousands of years old while the other is brand spanking new; one is easily portable while the other isn’t—I think there are three important distinctions that investors need to be aware of: volatility, taxation and correlation to the market.

Volatility I’ve already talked about.

Looking at taxation, Bitcoin is taxed the same as a stock, with a long-term capital gains rate of between 0% and 20%, depending on income level. Gold, on the other hand, is taxed as a collectible, meaning it carries a higher fixed rate of 28%, regardless of income. Point: Bitcoin.

And then there’s correlation. Gold has no correlation to the S&P 500, making it suitable for someone who wants to hedge against market risk. As a risk-on asset, Bitcoin has a slight correlation to the S&P. Point: Gold.

When you add all of this up, I believe it shows that gold has a small advantage over Bitcoin as a diversifier and store of value—at least for now. This could change as the Bitcoin network matures and its price swings stabilize.

 

Channelchek invites
you subscribe to the U.S. Global Investors YouTube channel by 
clicking here!

 

Suggested Reading:



Afghanistan is Sitting on a Gold Mine. Literally



What Metals Prices Can Tell us About the Economy





Afghanistan’s Mineral Resources are Estimated to be Worth $1 Trillion to $3 Trillion



Will U.S. Car Companies be Handed Different EV Advantages?

 

Of
Importance to Finance Majors (or Related Field)

Each year Noble Capital Markets, Channelchek, and some very generous and caring sponsors hold the Channelchek College Equity Research Challenge.

The Challenge invites students to compete with one another for high cash prizes awarded to the student and the student’s school – plus more (see rules). It may also provide high-value networking opportunities with veteran equity analysts.

Who can compete?

You don’t have to be a finance, accounting, or major in a related field to understand that up to $7500 for you, and an additional $5,000 to your school can be quite helpful.  If you are fully matriculated and interested, you likely qualify.

We invite
you to learn more. 
 

 

Stay up to date. Follow us:

 

Release – Kratos Receives $3.2 Million Contract Award for Next Generation Small Engine Development for National Security Program


Kratos Receives $3.2 Million Contract Award for Next Generation Small Engine Development for National Security Program

 

SAN DIEGO
Sept. 28, 2021 (GLOBE NEWSWIRE) — 
Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a leading National Security Solutions provider, announced today that its Kratos Turbine Technologies (KTT) Business has recently received an approximate 
$3.2 million contract award for the development of a Next Generation small engine for a National Security Program.  KTT is currently under contract and in development for several Next Generation turbojet, turbofan, and other engines for certain National Security priority areas, including unmanned aerial drone systems, cruise missiles, powered munitions and other platforms and systems.  Work under this recent contract award will be performed at a secure Kratos technical, engineering and development facility.  Due to customer, competitive and other considerations, no additional information is being provided related to this recent contract award.

Stacey Rock, President of KTT, said, “At Kratos, affordability is a technology, and KTT is focused on disrupting the small turbojet and turbofan class market area with a family of new, high performance, high power, affordable engines which address our customers’ rapidly expanding requirements.  We believe that Kratos’ digital engineering capabilities, which utilize an integrated digital approach with authoritative sources of system data and models across our entire organization’s functions and disciplines is a competitive differentiator for our Company and significant value contributor for our customers.”

About Kratos Defense & Security Solutions

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms and systems for United States National Security related customers, allies and commercial enterprises. Kratos is changing the way breakthrough technology for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research and streamlined development processes. At Kratos, affordability is a technology and we specialize in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training, combat systems and next generation turbo jet and turbo fan engine development. For more information go to www.KratosDefense.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended 
December 27, 2020, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the 
SEC by Kratos.

Press Contact:
Yolanda White
858-812-7302 Direct

Investor Information:
877-934-4687
investor@kratosdefense.com

Source: Kratos Defense & Security Solutions, Inc.